The independent platform for news, articles and advice for professionals in laboratory medicine

Rapid diagnosis of toxigenic Clostridium difficile using a novel LAMP technology

The identification of C. difficile carriers who have the potential to produce toxin can take up to four days, delaying patient isolation and increasing the chance of nosocomial spread of infection. Here, Laura Nottle considers the performance and benefits of a tcdB gene detection assay.

Toxigenic Clostridium difficile was identified as a cause of pseudomembranous colitis associated with antimicrobial therapy in the late 1970s.1,2 Since then, the incidence and severity of C. difficile-associated-disease (CDAD) has grown, and is one of the major causes of nosocomial infection in the UK.

C. difficile is an anaerobic spore-forming rod that is part of the normal intestinal flora of approximately 3% of healthy adults. It produces two large toxins, called toxin A (tcdA) and toxin B (tcdB), which act in the bowel to produce local tissue damage.3 Strains that produce only tcdB have been associated with CDAD, whereas strains that produce neither toxin are thought to be non-pathogenic.4

People may carry toxigenic C. difficile asymptomatically; however, serious sequelae can occur following overgrowth of C. difficile resulting from antimicrobial therapy. Institutional outbreaks of CDAD are frequently caused by ingestion of alcohol-resistant spores that are difficult to eradicate in the environment.

Log in or register FREE to read the rest

This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text. If you don't already have an account, please register with us completely free of charge.
Register

Upcoming Events

Pathology Horizons 2024

MacDonald Bath Spa Hotel, Bath
18-20 April, 2024

Diagnostics North East Conference 2024

The Catalyst, Newcastle upon Tyne
19 April, 2024

ECCMID 2024 - European Congress of Clinical Microbiology and Infectious Diseases

Fira Gran Via, 08038 Barcelona, Spain
27-30 April 2024

British Society for Microbial Technology Annual Microbiology Conference

UK Health Security Agency, Colindale, London
2 May 2024

EQA Reports: Interpreting Key Information & Troubleshooting Tips

ONLINE - Zoom
Thursday 16th May 2024

Participants’ Meeting: UK NEQAS Immunology, Immunochemistry & Allergy

Sheffield Hallam University, City Campus, Howard Street, Sheffield
24th May 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Upcoming Events

Pathology Horizons 2024

MacDonald Bath Spa Hotel, Bath
18-20 April, 2024

Diagnostics North East Conference 2024

The Catalyst, Newcastle upon Tyne
19 April, 2024

ECCMID 2024 - European Congress of Clinical Microbiology and Infectious Diseases

Fira Gran Via, 08038 Barcelona, Spain
27-30 April 2024

British Society for Microbial Technology Annual Microbiology Conference

UK Health Security Agency, Colindale, London
2 May 2024

EQA Reports: Interpreting Key Information & Troubleshooting Tips

ONLINE - Zoom
Thursday 16th May 2024

Participants’ Meeting: UK NEQAS Immunology, Immunochemistry & Allergy

Sheffield Hallam University, City Campus, Howard Street, Sheffield
24th May 2024

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999
www.step-communications.com
© 2024 Step Communications Ltd. Registered in England. Registration Number 3893025